



The KATP channel in migraine pathophysiology a novel therapeutic target for migraine

Al-Karagholi, Mohammad Al-Mahdi; Hansen, Jakob Møller; Severinsen, Johanne; Jansen-Olesen, Inger; Ashina, Messoud

Published in:
Journal of Headache and Pain

DOI:
[10.1186/s10194-017-0800-8](https://doi.org/10.1186/s10194-017-0800-8)

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY](#)

Citation for published version (APA):
Al-Karagholi, M. A-M., Hansen, J. M., Severinsen, J., Jansen-Olesen, I., & Ashina, M. (2017). The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine. *Journal of Headache and Pain*, 18, [90]. <https://doi.org/10.1186/s10194-017-0800-8>

REVIEW ARTICLE

Open Access



The K_{ATP} channel in migraine pathophysiology: a novel therapeutic target for migraine

Mohammad Al-Mahdi Al-Karagholi¹, Jakob Møller Hansen¹, Johanne Severinsen¹, Inger Jansen-Olesen^{1,2} and Messoud Ashina^{1*}

Abstract

Background: To review the distribution and function of K_{ATP} channels, describe the use of K_{ATP} channels openers in clinical trials and make the case that these channels may play a role in headache and migraine.

Discussion: K_{ATP} channels are widely present in the trigeminovascular system and play an important role in the regulation of tone in cerebral and meningeal arteries. Clinical trials using synthetic K_{ATP} channel openers report headache as a prevalent side effect in non-migraine sufferers, indicating that K_{ATP} channel opening may cause headache, possibly due to vascular mechanisms. Whether K_{ATP} channel openers can provoke migraine in migraine sufferers is not known.

Conclusion: We suggest that K_{ATP} channels may play an important role in migraine pathogenesis and could be a potential novel therapeutic anti-migraine target.

Keywords: Migraine, K_{ATP} channel, K_{ATP} channels, Headache, Levromakalim, Cromakalim

Introduction

Adenosine 5'-triphosphate-sensitive K^+ (K_{ATP}) channel openers have been used in clinical trials for the treatment of hypertension and asthma. The most common side effect mentioned during treatment with K_{ATP} channel openers was headache (62, 64, 66–79) (Tables 2 and 3). However, only little attention has been focused on the role of K_{ATP} channels in migraine pathophysiology.

K_{ATP} channels were originally identified in cardiomyocytes [1], but have also been found in several tissues, including pancreatic α - and β -cells, smooth muscle, skeletal muscle and central neurons [2, 3]. The channels belong to the family of inwardly rectifying K^+ channels that are inhibited at physiological intracellular levels ATP/ADP ratio. When intracellular ATP is reduced under conditions of metabolic challenges they open. K_{ATP} channels are critical in regulating insulin secretion,

controlling vascular tone, and protecting cells against metabolic stress [2, 4, 5].

Over the past three decades, some preclinical evidence has emerged indicating that K_{ATP} channels may play an important role in migraine pathophysiology. In particular, the vasodilation effect of K_{ATP} channels is relevant, since it has been established that endogenous neurotransmitters that trigger migraine attacks are often associated with dilation of cranial arteries [6].

Here we review preclinical and clinical studies on K_{ATP} channels and discuss the K_{ATP} channel as a novel therapeutic target for migraine treatment.

Molecular structure and isoforms

The K_{ATP} channel is a hetero-octameric complex that consists of four pore-forming K^+ inwardly rectifying (Kir) subunits and four regulatory sulfonylurea receptor (SUR) subunits [7].

The Kir6.x subunit exists in two isoforms, Kir6.1 and Kir6.2. The SUR subunit belongs to the ATP-binding cassette (ABC) transporter family, regulated by

* Correspondence: ashina@dadlnet.dk

¹Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, DK-2600 Copenhagen, Denmark


Full list of author information is available at the end of the article

sulfonylurea, with three isoforms, SUR1, SUR2A, and SUR2B [7, 8].

K_{ATP} channels have specific tissue expression with different compositions of Kir6.x and SUR subunits which lead to distinct functional properties (Figs. 1 and 2 and Table 1).

Channel function

K_{ATP} channel activity is controlled by changes in concentrations of intracellular ATP and magnesium adenosine diphosphate (Mg-ADP). K_{ATP} channels couple the metabolic state of the cell to the membrane potential and thus play a crucial role in many tissues under both






Fig. 2 Schematic diagram of the K_{ATP} channel. Kir6.x subunits have two transmembrane domains, and a large cytoplasmic domain including an inhibitory binding site for ATP [8, 84]. SUR subunits have many transmembrane domains and two intracellular nucleotide binding domains (NBD1 and NBD2), which stimulate opening of the channel after binding to MgADP [85]

physiological and pathological conditions [9]. K^+ channels participate in the regulation of vascular tone, including cerebral arteries [10]. When intracellular ATP is reduced, K_{ATP} channels become activated; K^+ efflux hyperpolarize the membrane and close voltage-operated Ca^{2+} -channels (VOCC). The result is a decrease in cytosolic Ca^{2+} concentration followed by relaxation of vascular smooth muscle cells and an increase in blood flow [11]. The same applies if cells are exposed to metabolic stress such as ischemia or hypoglycemia [12]. Closure of K^+ channels leads to membrane depolarization and constriction of the vessels [11]. In addition an increase in intracellular cAMP and cGMP levels activate K_{ATP} channels to produce vasodilation [11]. Synthetic K_{ATP} channel openers (like levromakalim and cromakalim) and

blockers (like glibenclamide, second generation of sulfonylurea and PNU37883A) directly activate or inhibit the vascular K_{ATP} channels, respectively [9] (Fig. 3).

Distribution of K_{ATP} channels in migraine related structures

Intracranial arteries

K_{ATP} channels are present and functional in intracranial arteries [13–15]. They are found in vascular smooth muscle cells and vascular endothelial cells [16, 17]. In rat cerebral arteries, the distribution of K_{ATP} channels varies with vessel size and brain region [18]. Real time polymerase chain reaction (RT-PCR) analysis revealed Kir6.1 and SUR2B subunits in middle meningeal artery (MMA) and middle cerebral artery (MCA) in rats and pigs [19, 20]. This profile of K_{ATP} channels is also identified in human MMA [21] (Table 1).

Trigeminal ganglion and trigeminal nucleus caudalis

Kir6.1, Kir6.2, SUR1 and SUR2 are expressed in the trigeminal ganglion and trigeminal nucleus caudalis [22] (Table 1). In trigeminal neurons Kir 6.1 and Kir 6.2 immunoreactivity were expressed in cells with all soma sizes in all three divisions of the trigeminal ganglion [23].


K_{ATP} channels openers and migraine signaling pathways

A number of endogenous vasoactive signaling molecules have been implicated in migraine [6], and K_{ATP} channels may interact with these molecules.

Table 1 Distribution of K_{ATP} channels

Subtypes of K_{ATP} channels	Tissue expression	Migraine related structures
Kir6.2/SUR1	Pancreas and brain	DRG, TG and TNC from rats (20–24, 26).
Kir6.2/SUR2A	Cardiac and skeletal muscle	
Kir6.2/SUR2B	Smooth muscle	DRG, TG, TNC, BA and MCA from rats(20–24, 26).
Kir6.1/SUR2B	Smooth muscle	MMA from rats, pigs and human; MCA from rats and pigs; BA, DRG, TG and TNC from rats (20–24, 26).

DRG Dorsal root ganglia, TG trigeminal ganglion, TNC trigeminal nucleus caudatus, BA basilar artery, MMA middle meningeal artery, MCA middle cerebral artery



Nitric oxide (NO)

In humans, infusion of the NO donor, glyceryl trinitrate, and inhibition of the breakdown of cGMP by sildenafil [24] provoke migraine attacks in migraineurs [25–27]. The NO-cGMP signaling pathway is involved in the relaxation of vascular smooth muscle [28]. In vitro studies with cerebral arteries isolated from rat and piglet and extra-cerebral arteries from rabbit reported that activation (opening) of K_{ATP} channels contributed to both cAMP- and cGMP-mediated vasodilation [29–31]. Yuan et al. [32] reported that sildenafil-induced vasodilation in porcine retinal arterioles was significantly inhibited by glibenclamide and suggested that cGMP signaling triggers opening of K_{ATP} channels. In contrast, NO-induced dural and pial artery dilation in rats was not attenuated by the K_{ATP} channel blocker, glibenclamide [33]. Together, these data suggest that interspecies differences are likely to explain the discrepancy in findings of the role of K_{ATP} channels in NO-induced vasodilation.


Calcitonin gene-related peptide (CGRP)

CGRP is one of the most potent endogenous vasodilators and major arteries in the intracranial circulation of

man and animals are innervated by CGRP-containing nerve fibers [34–36]. Efficacy of CGRP antagonism is established in acute [37, 38] and preventive treatment of migraine [39]. CGRP activates vascular smooth muscle K_{ATP} channels indirectly through adenylate cyclase and protein kinase A (PKA) phosphorylation (Fig. 4) [40–43]. In rats, CGRP-induced dilation of the dural and pial arteries in vivo was shown to be inhibited by glibenclamide [33], but K_{ATP} channel openers do not interact with CGRP release in trigeminal ganglion and trigeminal nucleus caudalis [22]. This suggests that K_{ATP} channels are involved in CGRP-induced intracranial vasodilation.

Pituitary adenylate cyclase activating polypeptide (PACAP)

Pituitary adenylate cyclase activating polypeptide (PACAP) is a potent endothelium independent vasodilator of various vascular beds, including cerebral arteries [44, 45]. In vivo and in vitro studies have demonstrated that PACAP dilates cranial arteries in different species, e.g. human cerebral arteries [34, 46, 47], pig pia artery, canine basilar artery, cat cerebral arteries, rabbit posterior cerebral arteries and rat middle cerebral arteries [48–52]. Emerging



data suggest that PACAP or its receptors are a promising target for migraine therapeutics [53]. PACAP has three types of receptors; Pituitary adenylate cyclase PAC₁ (pituitary adenylate cyclase receptor 1), VPAC₁ (vasoactive intestinal peptide and pituitary adenylate cyclase receptor 1) and VPAC₂ (vasoactive intestinal peptide and pituitary adenylate cyclase receptor 2) [54] the two latter ones are also activated by vasoactive intestinal peptide and all three receptors are found in cerebral artery smooth muscle cells [55]. Through these receptors, PACAP leads to an increase in intracellular cAMP, which activates PKA and produces vasodilation by several mechanisms including activation of K_{ATP} channels (Fig. 4) [45]. Interestingly, glibenclamide could partially inhibit PACAP induced vasodilation in cerebral, coronary and pulmonary arteries, suggesting that PACAP may also activate K_{ATP} channels [44, 45].

Prostaglandins

Prostacyclin (PGI₂) activates and sensitizes meningeal sensory afferents, and provokes immediate migraine-like attacks in migraine sufferers [56]. PGI₂ also increases

K_{ATP} channel activity in vascular smooth muscle preparations by cAMP-dependent PKA activation [57] (Fig. 4).

Headache induced by K_{ATP} channels openers

In the late 80's there was a tremendous interest in developing novel K_{ATP} channel openers for hypertension, angina pectoris and asthma. Three pharmacological drugs were developed, pinacidil, nicorandil and levromakalim. One of the most common adverse events after treatment reported in these studies was headache [58–63].

Six clinical trials with pinacidil have been published for treatment of essential hypertension. Between 7% and 21% of the patients reported headache as an adverse effect (Table 2).

Nicorandil was tested for the treatment of angina pectoris and ischemic heart disease. 23% to 88% of the patients reported headache as an adverse event (Table 3). The high incidence of headache is likely due to the mixed K_{ATP} channel opener and NO donor properties of nicorandil which thus cause vasodilation via two separate mechanisms.

Levromakalim was investigated for the treatment of asthma and essential hypertension. In these studies

Table 2 Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with pinacidil

Paper	Study design	Dose (daily)	Indication	No. of patients	Headache No.
Muiesan et al. 1985, Eur. J. Clin. Pharmacol [86].	RCT	30–75 mg	Essential hypertension	30	2 (7%)
Laher & Hickey 1985, J. Int. Med. Res [87].	Open label	12.5 mg	Healthy volunteers	12	1 (8%)
D’Arcy et al. 1985, Eur. J. Clin. Pharmacol [88].	Open label	20–100 mg	Essential hypertension	23	4 (17%)
Zachariah et al. 1986, Eur. J. Clin. Pharmacol [89].	RCT	62 mg (mean)	Essential hypertension	23	—
Sterndorff & Johansen 1988, Acta Med. Scand [90].	RCT	25–100 mg	Essential hypertension	71	7 (10%)
Goldberg 1988, J. Cardiovasc. Pharmacol [91].	RCT	25–100 mg	Essential hypertension	145	31 (21%)

Table 3 Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with nicorandil

Paper	Study design	Dose (daily)	Indication	No. of patients	Headache No.
Camm & Maltz, 1989, Am. J. Cardiol [92].	RCT	20–60 mg	Angina pectoris	8	20 mg 50% 40 mg 88% 60 mg 67%
Raftery et al. 1993, Eur. Heart Journal [93].	RCT	20 mg and 40 mg	Angina pectoris	18	11 (61%)
Roland 1993, Eur. Heart Journal [94].	Review	10–80 mg	Angina pectoris	1680	36%
Wolf et al. 1993, Eur.J.Clin.Pharmacol [95].	RCT	20–200 µg i.v.	Healthy volunteers	48	19 (40%)
Witchitz & Darmaon, 1995, Cardiovasc. Drugs& Therap [96].	Open label	20–40 mg	Angina pectoris	197	45 (23%)
Dunn et al. 1999, Pharmacoepidemiology and Drug safety [97].	Prescription-event monitoring (PEM) study	Varying	Angina pectoris & ischemic heart disease	13,260	477 (4%)

between 29% and 76% of the patients reported headache as an adverse event (Table 4).

The selective synthetic K_{ATP} channel openers levcromakalim and pinacidil have been shown to induce dilation in rat cranial arteries [13, 15, 19] and in isolated human cerebral arteries [64]. Moreover, the arterial dilation can be inhibited by synthetic K_{ATP} channel blockers like glibenclamide [10, 33] and PNU37883A [21, 65] (Fig. 3). These findings suggest that high incidences of headache could be due to vasoactive effect of the K_{ATP} channel openers in pain-sensitive extra- and/or intracerebral arteries.

Discussion and future perspectives

K_{ATP} channels are expressed in migraine-related structures such as the cranial arteries, TG and TNC [18–22, 66]. K_{ATP} channels are also connected to a number of key molecules in migraine pathogenesis, particularly nitric oxide, CGRP, PACAP and PGI_2 known to provoke migraine attacks [56, 67–71]. Therefore, the K_{ATP} channels are interesting in migraine context.

Human experimental models have demonstrated that the activation of the cAMP and cGMP pathways can trigger headache in healthy volunteers and migraine attacks in migraine sufferers [6, 71, 72]. The cAMP and cGMP signaling pathways are crucial in the activation of K_{ATP} channels, which result in the relaxation of smooth muscle [29–31]. Furthermore, synthetic K_{ATP} channel openers like levcromakalim and pinacidil trigger headache in non-migraine patients [58–63]. Although a detailed description of levcromakalim- and pinacidil-

induced headache and accompanying symptoms are lacking, these data support a role of K_{ATP} channels in migraine headache. Because K_{ATP} channel openers were tested for other indications, there are no available data on the potential migraine-inducing effects of pinacidil and levcromakalim in migraine patients. It is conceivable that both headache and migraine are underreported as adverse events, as was found for the phosphodiesterase inhibitors, cilostazol and sildenafil [73, 74].

In addition to the vasoactive effects, the K_{ATP} channels might also tap into other parts of the migraine cascade. For a number of patients, migraine attacks are associated with transient focal neurological symptoms called the aura [75], possibly caused by cortical spread depression (CSD) [76]. During CSD K^+ conductance is increased, and CSD may be inhibited by Kir antagonist [77]. The fact that K_{ATP} channels open under cellular stress, as seen during long lasting depolarizations, could provide a link between K_{ATP} channels, CSD and migraine aura.

With regard to the migraine pain, it is worth noting that K_{ATP} channels are also found in peripheral nociceptive fibers [78] and activation of these channels play a crucial role in anti-nociception at both spinal and supra-spinal levels [23, 79]. The exact role of these findings in the headache induced by K_{ATP} channel openers is unknown.

If K_{ATP} channel openers are in fact able to trigger migraine, the next step to consider is whether K_{ATP} channel antagonists can relieve migraine. K_{ATP} blockers for the treatment of migraine should be selective for the Kir6.1/SUR2B subtype because of its dominant presence in vascular tissue (Table 1). The necessity of a subtype

Table 4 Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with levcromakalim

Paper	Study design	Dose (daily)	Indication	No. of patients	Headache No.
Singer et al. 1989, J. Hypertens [98].	RCT	1.5 mg	Essential hypertension	8	4 (50%)
Williams et al. 1990, Lancet [60].	RCT	1.5 mg	Asthma	16	10 (62%)
Kidney et al. 1993, Thorax [62].	RCT	0.125–0.5 mg	Asthma	25	19 (76%)
Suzuki et al. 1995, Arzneim.-Forsch./Drug Res [99].	Open label	0.5–1.0 mg	Essential hypertension	14	4 (29%)

specific blocker is unavoidable because of occurrence of different subtypes in different tissues. Glibenclamide cannot be used due to its high affinity to the Kir6.2/SUR1 subtype of K_{ATP} channels present in the pancreas with hypoglycemia as a side effect [80]. PNU-37883A is a Kir6.1 selective K_{ATP} channel blocker that was originally developed as a diuretic drug [81, 82]. The drug was not approved to human studies because of its cardiac depressant activity in animal studies [83]. This precludes further clinical development of PNU-37883A due to possible serious adverse events but may not exclude further investigations in other blockers against Kir6.1 subunit because it is not clear if all blockers against Kir6.1 subunit have non-favorable effects. These findings indicate that the SUR2B subunit and the Kir6.1 subunit should be a potential target for the treatment of migraine, but proof of concept studies are needed to examine this hypothesis.

Conclusion

Emerging evidence suggests that K_{ATP} channels could be involved in the pathophysiology of migraine. K_{ATP} channels exist in structures which are believed to be linked to the pathophysiology of migraine, including cerebral and meningeal arteries and the trigeminal system [19–22]. It is established that the cAMP signaling pathway and possibly cGMP signaling pathway are involved in the activation of K_{ATP} channels [29–31]. This is interesting in migraine contexts, as the two signaling pathways are likely to be crucial in the development of a migraine attack.

We suggest that the presented clinical and theoretical evidence support further studies of K_{ATP} channel openers in migraine context. Future human studies will help clarify the role of K_{ATP} channels in the pathophysiology of migraine.

Abbreviations

ABC transporter: ATP-binding cassette transporter; BA: Basilar artery; CGRP: Calcitonin gene-related peptide; CSD: Cortical spread depression; DRG: Dorsal root ganglia; K_{ATP} channel: Adenosine 5'-triphosphate-sensitive K^+ channel; Kir: K^+ inwardly rectifying; MCA: Middle cerebral artery; Mg-ADP: Magnesium adenosine diphosphate; MMA: Middle meningeal artery; NBD: Nucleotide binding domains; NO: Nitric oxide; PACAP: Pituitary adenylate cyclase activating polypeptide; PGI₂: Prostacyclin; SUR: Sulfonylurea receptor; TG: Trigeminal ganglion; TNC: Trigeminal nucleus caudatus; VOCC: Voltage-operated Ca^{2+} -channels

Funding

This article was supported by the Lundbeck Foundation.

Authors' contributions

MMK designed and performed the review, with the help of JMH, JS, IJO and MA. MMK drafted the manuscript with the help of JMH, JS, IJO and MA. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, DK-2600 Copenhagen, Denmark. ²Danish Headache Center, Department of Neurology, Glostrup Research Park, Rigshospitalet Glostrup, Copenhagen, Denmark.

Received: 3 July 2017 Accepted: 15 August 2017

Published online: 23 August 2017

References

- Noma A (1983) ATP-regulated K^+ channels in cardiac muscle. *Nature* 305: 147–148. doi:10.1038/305147a0
- Aguilar-Bryan L, Bryan J (1999) Molecular biology of adenosine triphosphate-sensitive potassium channels. *Endocr Rev* 20:101–135. doi:10.1210/er.20.2.101
- Dunn-Meynell AA, Rawson NE, Levin BE (1998) Distribution and phenotype of neurons containing the ATP-sensitive K^+ channel in rat brain. *Brain Res* 814:41–54. doi:10.1016/S0006-8993(98)00956-1
- Yamada K, Inagaki N (2005) Neuroprotection by KATP channels. *J Mol Cell Cardiol* 38:945–949. doi:10.1016/j.jmcc.2004.11.020
- Saito T, Fujiwara Y, Fujiwara R, et al (2002) Experimental biology 2001 symposium potassium channels that regulate vascular tone : which are the important players ? ROLE OF AUGMENTED EXPRESSION OF INTERMEDIATE-CONDUCTANCE Ca^{2+} -ACTIVATED K^+ CHANNELS IN. 324–329
- Ashina M, Hansen JM, Olesen J (2013) Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. *Cephalalgia* 33: 540–553. doi:10.1177/0333102412475234
- Clement JP, Kunjilwar K, Gonzalez G et al (1997) Association and stoichiometry of K(ATP) channel subunits. *Neuron* 18:827–838. doi:10.1016/S0896-6273(00)80321-9
- Shyng S-L, Nichols CG (1997) Octameric stoichiometry of the K_{ATP} Channel complex. *J Gen Physiol* 110:655–664. doi:10.1085/jgp.110.6.655
- Rubaiy HN (2016) The therapeutic agents that target ATP-sensitive potassium channels. *Acta Pharma* 66:23–34. doi:10.1515/acph-2015-0040
- Faraci FM, Sobey CG (1998) Role of potassium channels in regulation of cerebral vascular tone. *J Cereb Blood Flow Metab* 18:1047–1063. doi:10.1097/00004647-199810000-00001
- Chrissobolis S, Sobey CG (2003) Inwardly rectifying potassium channels in the regulation of vascular tone. *Curr Drug Targets* 4:281–289
- Henn MC, Janjua MB, Zhang H et al (2016) Increased tolerance to stress in cardiac expressed gain-of-function of adenosine triphosphate-sensitive potassium channel subunit Kir6.1. *J Surg Res* 206:460–465. doi:10.1016/j.jss.2016.08.043
- Gozalov A, Petersen KA, Mortensen C et al (2005) Role of KATP channels in the regulation of rat dura and pia artery diameter. *Cephalalgia* 25:249–260. doi:10.1111/j.1468-2982.2004.00848.x
- Kitazono T, Faraci FM, Taguchi H, Heistad DD (1995) Role of potassium channels in cerebral blood vessels. *Stroke* 26:1713–1723
- Jansen-Olesen I, Mortensen CH, El-Bariaki N, Ploug KB (2005) Characterization of KATP-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression. *Eur J Pharmacol* 523:109–118. doi:10.1016/j.ejphar.2005.08.028
- Janigro D, West GA, Gordon EL, Winn HR (1993) ATP-sensitive K^+ channels in rat aorta and brain microvascular endothelial cells. *Am J Phys* 265:C812–C821
- Faraci FM, Heistad DD (1998) Regulation of the Cerebral Circulation: Role of Endothelium and Potassium Channels. *Physiol Rev* 78:53–97
- McPherson GA, Stork AP (1992) The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K^+ channel openers. *Br J Pharmacol* 105:51–58. doi:10.1111/j.1476-5381.1992.tb14209.x
- Ploug KB, Edvinsson L, Olesen J, Jansen-Olesen I (2006) Pharmacological and molecular comparison of KATP channels in rat basilar and middle cerebral arteries. *Eur J Pharmacol* 553:254–262. doi:10.1016/j.ejphar.2006.09.053
- Ploug KB, Baun M, Hay-Schmidt A et al (2010) Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. *Eur J Pharmacol* 637:109–117. doi:10.1016/j.ejphar.2010.03.027

21. Ploug KB, Sørensen MA, Strøbech L et al (2008) KATP channels in pig and human intracranial arteries. *Eur J Pharmacol* 601:43–49. doi:10.1016/j.ejphar.2008.10.041
22. Ploug KB, Amrutkar DV, Baun M et al (2012) K(ATP) channel openers in the trigeminovascular system. *Cephalalgia* 32:55–65. doi:10.1177/0333102411430266
23. Niu K, Saloman JL, Zhang Y, Ro JY (2011) Sex differences in the contribution of ATP-sensitive K⁺ channels in trigeminal ganglia under an acute muscle pain condition. *Neuroscience* 180:344–352. doi:10.1016/j.neuroscience.2011.01.045
24. Leoni LAB, Leite GS, Wichi RB, Rodrigues B (2013) Sildenafil: two decades of benefits or risks? *Aging Male* 16:85–91. doi:10.3109/13685538.2013.801952
25. Kruse C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. *Brain* 126:241–247. doi:10.1093/brain/awg009
26. Olesen J, Thomsen LL, Lassen LH, Olesen J (1995) The nitric oxide hypothesis of migraine and other vascular headaches. *Cephalalgia* 15:94–100. doi:10.1046/j.1468-2982.1995.015002094.x
27. Olesen J, Iversen HK, Thomsen LL (1993) Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. *Neuroreport* 4:1027–1030
28. Niehaus L, Gottschalk S, Weber U (1998) Effect of drug-induced vasodilatation of basal brain arteries with nitroglycerin on blood flow velocity and volume flow in the middle cerebral artery. *Ultraschall Med* 19:225–229. doi:10.1055/s-2007-1000495
29. Armstead WM (1996) Role of ATP-sensitive K⁺ channels in cGMP-mediated pial artery vasodilation. *Am J Phys* 270:H423–H426
30. Hempelmann RG, Ziegler A, Mehdorn HM (2001) Role of potassium channels in the relaxation induced by the nitric oxide (NO) donor DEA / NO in the isolated rat basilar artery. *Neurosci Lett* 313:21–24
31. Murphy ME, Brayden JE (1995) Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. *J Physiol* 486 (Pt 1):47–58. doi:10.1113/jphysiol.1995.sp020789
32. Yuan Z, Hein TW, Rosa RH, Kuo L (2008) Sildenafil (viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition. *Investig Ophthalmol Vis Sci* 49:720–725. doi:10.1167/iov.07-1208
33. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J (2008) Role of KATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. *Headache* 48:1202–1213. doi:10.1111/j.1526-4610.2008.01205.x
34. Jansen-Olesen I, Gulbenkian S, Engel U et al (2004) Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. *Peptides* 25:2105–2114. doi:10.1016/j.peptides.2004.08.002
35. Edvinsson L, Gulbenkian S, Barroso CP et al (1998) Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. *Peptides* 19:1213–1225. doi:10.1016/S0196-9781(98)00066-7
36. Edvinsson L, Ekman R, Jansen I et al (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. *J Cereb Blood Flow Metab* 7:720–728. doi:10.1038/jcbfm.1987.126
37. Olesen J, Diener H, Husstedt IW, et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *Society* 1104–1110
38. Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. *Lancet* 372:2115–2123. doi:10.1016/S0140-6736(08)61626-8
39. Hou M, Xing H, Cai Y et al (2017) The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. *J Headache Pain* 18:42. doi:10.1186/s10194-017-0750-1
40. Nelson MT, Huang Y, Brayden JE et al (1990) Arterial dilations in response to calcitonin gene-related peptide involve activation of K⁺ channels. *Nature* 344:770–773. doi:10.1038/344770a0
41. Quayle JM, Bonev AD, Brayden JE, Nelson MT (1994) Calcitonin gene-related peptide activated ATP-sensitive K⁺ currents in rabbit arterial smooth muscle via protein kinase a. *J Physiol* 475:9–13. doi:10.1113/jphysiol.1994.sp020045
42. Nakaya Y, City T (1995) Calcitonin gene-related peptide activates the K⁺ channels of vascular smooth muscle cells via adenylate cyclase. 332–336
43. Wellman GC, Quayle JM, Standen NB (1998) ATP-sensitive K⁺ channel activation by calcitonin gene-related peptide and protein kinase a in pig coronary arterial smooth muscle. *J Physiol* 507(1):117–129
44. Bruch L, Rubel S, Kästner A, et al (1998) Pituitary adenylate cyclase activating peptides relax human pulmonary arteries by opening of K ATP and K Ca channels. 586–587
45. Chalovich JM, Eisenberg E (2005) NIH public access. *Biophys Chem* 257: 2432–2437. doi:10.1016/j.bjmm.2010.12.017 Two stage
46. Amin FM, Asghar MS, Guo S, et al (2011) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. 32:140–149. doi:10.1177/0333102411431333
47. Amin FM, Hougaard A, Schytz HW et al (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. *Brain* 137:779–794. doi:10.1093/brain/awt369
48. Erdling A, Sheykhzade M, Maddahi A et al (2013) VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. *Neuropeptides* 47:85–92. doi:10.1016/j.npep.2012.12.005
49. Dalsgaard T, Hannibal J, Fahrenkrug J et al (2003) VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. *Regul Pept* 110:179–188. doi:10.1016/S0167-0115(02)00205-7
50. Uddman R, Goadsby PJ, Jansen I, Edvinsson L (1993) PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. *J Cereb Blood Flow Metab* 13:291–297. doi:10.1038/jcbfm.1993.36
51. Tong S, Parfenova H, Shibata M et al (1993) Pituitary adenylate cyclase-activating polypeptide dilates cerebral arterioles of newborn pigs. *Proc Soc Exp Biol Med* 203:343–347
52. Seki Y, Suzuki Y, Baskaya MK et al (1995) The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. *Eur J Pharmacol* 275:259–266
53. Zagami AS, Edvinsson L, Goadsby PJ (2014) Pituitary adenylate cyclase activating polypeptide and migraine. *Ann Clin Transl Neurol* 1:1036–1040. doi:10.1002/acn3.113
54. Vaudry D, Falluel-morel A, Bourgault S et al (2009) Pituitary Adenylate Cyclase-activating polypeptide and its receptors : 20 years after the discovery. *Pept Res* 61:283–357. doi:10.1124/pr.109.001370.283
55. Syed AU, Koide M, Braas KM et al (2012) Pituitary adenylate cyclase-activating polypeptide (PACAP) potentially dilates middle meningeal arteries: implications for migraine. *J Mol Neurosci* 48:574–583. doi:10.1007/s12031-012-9851-0
56. Wienecke T, Olesen J, Ashina M (2010) Prostaglandin I₂ (epoprostenol) triggers migraine-like attacks in migraineurs. *Cephalalgia* 30:179–190. doi:10.1111/j.1468-2982.2009.01923.x
57. Ray CJ, Marshall JM (2006) The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. *J Physiol* 570:85–96. doi:10.1113/jphysiol.2005.099390
58. Thomas P, Dixon MS, Winterton SJ, Sheridan DJ (1990) Acute haemodynamic effects of cromakalim in patients with angina pectoris. *Br J Clin Pharmacol* 29:325–331
59. Antihypertensive Effect of Levocromakalim in patients with essential hypertension.pdf
60. Williams AJ, Lee TH, Vyse T et al (1990) Attenuation of nocturnal asthma by cromakalim. *Lancet* 336:334–336. doi:10.1016/0140-6736(90)91877-D
61. von Nguyen P, Holliwell DL, Davis A et al (1991) Effects of the potassium channel activator, cromakalim, on arterial and cardiac responses to norepinephrine, angiotensin II, and isoproterenol in normotensive men. *J Cardiovasc Pharmacol* 18:797–806
62. Kidney JC, Fuller RW, Worsdell YM et al (1993) Effect of an oral potassium channel activator, BRL 38227, on airway function and responsiveness in asthmatic patients: comparison with oral salbutamol. *Thorax* 48:130–133. doi:10.1136/thx.48.2.130
63. Fox JS, Whitehead EM, Shanks RG (1991) Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers. *Br J Clin Pharmacol* 32:45–49
64. Hempelmann RG, Barth HL, Mehdorn HM et al (1995) Effects of potassium channel openers in isolated human cerebral arteries. *Neurosurgery* 37:1146–1153
65. Ploug KB, Boni LJ, Baun M et al (2008) K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries. *Br J Pharmacol* 154:72–81. doi:10.1038/bjp.2008.86

66. Zoga V, Kawano T, Liang M-Y et al (2010) KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy. *Mol Pain* 6:6. doi:10.1186/1744-8069-6-6
67. Olesen J, Jansen-Olesen I (2000) Nitric oxide mechanisms in migraine. *Pathol Biol (Paris)* 48:648–657
68. Villalón CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. *Pharmacol Ther* 124:309–323. doi:10.1016/j.pharmthera.2009.09.003
69. Schytz HW, Birk S, Wienecke T et al (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. *Brain* 132:16–25. doi:10.1093/brain/awn307
70. Kaiser EA, Russo AF (2013) CGRP and migraine: could PACAP play a role too? *Neuropeptides* 47:451–461. doi:10.1016/j.nepep.2013.10.010
71. Schytz HW, Schoonman GG, Ashina M (2010) What have we learnt from triggering migraine? *Curr Opin Neurol* 23:259–265. doi:10.1097/WCO.0b013e328337b884
72. Garthwaite J, Charles SL, Chess-Williams R (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. *Nature* 336:403–405. doi:10.1038/332141a0
73. Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. *Brain* 137:2951–2959. doi:10.1093/brain/awu244
74. Dinn RB, Wall M (2006) Tadalafil associated with typical migraine aura without headache. *Cephalalgia* 26:1344–1346. doi:10.1111/j.1468-2982.2006.01188.x
75. Road C (2013) The international classification of headache disorders, 3rd edition (beta version). *Cephalalgia* 33:629–808. doi:10.1177/0333102413485658
76. Lauritzen M (1994) Pathophysiology of the migraine aura. The spreading depression theory. *Brain* 117(Pt 1):199–210
77. Wendt S, Wogram E, Korvers L, Kettenmann H (2016) Experimental cortical spreading depression induces NMDA receptor dependent potassium currents in microglia. *J Neurosci* 36:6165–6174. doi:10.1523/JNEUROSCI.4498-15.2016
78. Staurengo-Ferrari L, Zarpelon AC, Longhi-Balbinot DT et al (2014) Nitroxylin inhibits overt pain-like behavior in mice: role of cGMP/PKG/ATP-sensitive potassium channel signaling pathway. *Pharmacol Reports* 66:691–698. doi:10.1016/j.pharep.2014.04.003
79. North RA, Williams JT, Surprenant A, Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. *Neurobiology* 84:5487–5491
80. Riefflin A, Ayyagari U, Manley SE et al (2015) The effect of glibenclamide on insulin secretion at normal glucose concentrations. *Diabetologia* 58:43–49. doi:10.1007/s00125-014-3399-1
81. Perricone SC, Humphrey SJ, Skaletzky LL, et al (1994) In rats and dogs. 3693–3700
82. Meisneri KD, Humphrey SJ, Khan SA et al (1993) 4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexylhydrochloride (U-37883A): pharmacological characterization of a novel antagonist of vascular ATP-sensitive K⁺ channel openers. *J Pharmacol Exp Ther* 266:655–665
83. Humphrey SJ, Smith MP, Cimini MG et al (1996) Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines. *Methods Find Exp Clin Pharmacol* 18:247–260
84. Shyng SL, Nichols CG (1998) Membrane phospholipid control of nucleotide sensitivity of KATP channels. *Science* 282(80):1138–1141. doi:10.1126/science.282.5391.1138
85. Davies GC, Thornton MJ, Jenner TJ et al (2005) Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. *J Invest Dermatol* 124:686–694. doi:10.1111/j.0022-202X.2005.23643.x
86. Muiesan G, Fariello R, Muiesan ML, Christensen OE (1985) Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension. *Eur J Clin Pharmacol* 28:495–499
87. Laher MS, Hickey MP (1985) Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers. *J Int Med Res* 13:159–162. doi:10.1177/030006058501300302
88. D'Arcy V, Laher M, McCoy D et al (1985) Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. *Eur J Clin Pharmacol* 28:347–349
89. Zachariah PK, Sheps SG, Schirger A et al (1986) Antihypertensive efficacy of pinacidil—automatic ambulatory blood pressure monitoring. *Eur J Clin Pharmacol* 31:133–141
90. Sterndorff B, Johansen P (1988) The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice. *Acta Med Scand* 224:329–336
91. Goldberg MR (1988) Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. *J Cardiovasc Pharmacol* 12(Suppl 2):S41–S47
92. Camm AJ, Maltz MB (1989) A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. *Am J Cardiol* 63:61J–65J
93. Raftery EB, Lahiri A, Hughes LO, Rose EL (1993) A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. *Eur heart J* 14(Suppl B):35–39
94. Roland E (1993) Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. *Eur heart J* 14(Suppl B):48–52
95. Wolf DL, Ferry JJ, Hearron AE et al (1993) The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers. *Eur J Clin Pharmacol* 44:27–33
96. Witchitz S, Darmon JY (1995) Nicorandil safety in the long-term treatment of coronary heart disease. *Cardiovasc Drugs Ther* 9(Suppl 2):237–243
97. Dunn N, Bm MA, Freemantle S, et al (1999) Safety profile of Nicorandil in prescription-event monitoring (PEM) study. 205:197–205
98. Singer DR, Markandu ND, Miller MA et al (1989) Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915). *J Hypertens Suppl* 7:S294–S295
99. Suzuki S, Yano K, Kusano S, Hashimoto T (1995) Antihypertensive effect of levromakalim in patients with essential hypertension. Study by 24-h ambulatory blood pressure monitoring. *Arzneimittelforschung* 45:859–864

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com